NEW YORK (TheStreet) -- Shares of AbbVie (ABBV) - Get Report  are up 0.73% to $64.92 this afternoon ahead of the company's 2016 second quarter earnings report, due out on Friday before the opening bell.

Analysts surveyed by Thomson Reuters are looking for the company to report earnings of $1.20 per share on revenue of $6.2 billion.

For the 2015 second quarter, AbbVie reported earnings of $1.08 per share and revenue of $5.47 billion.

The company has beat analysts' expectations for the past three earnings reports. For this quarter, AbbVie expects its immunosuppressant drug Humira to remain the main growth driver for the company due to improved awareness, strong underlying demand and favorable clinical data, Zacks reports.

AbbVie released a hepatitis C therapy drug earlier this year meant to carve out part of the market from competitor Gilead (GILD), for whom hepatitis C medication is its major business.

AbbVie is a North Chicago, IL-based research biopharmaceutical company.

(AbbVie is held in David Peltier's Dividend Stock Advisor portfolio. See all of his holdings with a free trial.)

Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

TheStreet Ratings rated this stock as a "buy" with a ratings score of A.

The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, robust revenue growth, good cash flow from operations and expanding profit margins. TheStreet Ratings feels its strengths outweigh the fact that the company has had lackluster performance in the stock itself.

You can view the full analysis from the report here: ABBV

Image placeholder title